Intrauterine devices and endometrial cancer risk: A pooled analysis of the Epidemiology of Endometrial Cancer Consortium
暂无分享,去创建一个
C. Friedenreich | H. Adami | E. Negri | A. Spurdle | E. Weiderpass | M. Sherman | X. Shu | Y. Xiang | L. Brinton | L. Bernstein | S. Gapstur | S. Olson | H. Risch | Herbert Yu | A. Zeleniuch‐Jacquotte | J. Lacey | J. Doherty | S. McCann | C. Vecchia | Wanghong Xu | S. Beresford | Hannah P. Yang | A. Magliocco | L. Wise | Chu Chen | P. Webb | L. Cook | L. Rosenberg | F. Levi | M. Gaudet | Lingeng Lu | I. Vivo | C. Nagle | J. Prescott | Alpa V. Patel | A. Felix | S. Petruzella | Dierdre Hill | Xiaolin Liang | A. Patel | P. Horn‐Ross | J. Palmer
[1] S. Grénman,et al. Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland , 2014, Obstetrics and gynecology.
[2] M. Pike,et al. Type I and II endometrial cancers: have they different risk factors? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P. Hartge,et al. An aggregated analysis of hormonal factors and endometrial cancer risk by parity , 2013, Cancer.
[4] I. Sinai,et al. Contraceptive failure in the United States. , 2012, Contraception.
[5] P. Saxena,et al. Comparison of levonorgestrel and copper releasing intrauterine contraceptive device on body iron stores and menstrual bleeding patterns: experience on Indian women. , 2012, European review for medical and pharmacological sciences.
[6] A. Mantovani,et al. Cancer-related inflammation: common themes and therapeutic opportunities. , 2012, Seminars in cancer biology.
[7] A. Kulczycki,et al. Revival of the intrauterine device: increased insertions among US women with employer-sponsored insurance, 2002-2008. , 2012, Contraception.
[8] A. Spurdle,et al. Use of talcum powder and endometrial cancer risk , 2012, Cancer Causes & Control.
[9] M. Irwin,et al. Physical activity and endometrial cancer in a population-based case–control study , 2011, Cancer Causes & Control.
[10] C. Friedenreich,et al. Case–control study of lifetime total physical activity and endometrial cancer risk , 2010, Cancer Causes & Control.
[11] N. Weiss,et al. Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. , 2009, American journal of epidemiology.
[12] L. Brinton,et al. Timing of births and endometrial cancer risk in Swedish women , 2009, Cancer Causes & Control.
[13] Shannon M. Lynch,et al. Maximizing resources to study an uncommon cancer: E2C2—Epidemiology of Endometrial Cancer Consortium , 2009, Cancer Causes & Control.
[14] L. Dennis,et al. Meta-analysis of intrauterine device use and risk of endometrial cancer. , 2008, Annals of epidemiology.
[15] C. Sima,et al. Variants in hormone biosynthesis genes and risk of endometrial cancer , 2008, Cancer Causes & Control.
[16] R. Broaddus,et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Curtis,et al. Neoplasia with use of intrauterine devices. , 2007, Contraception.
[18] H. Critchley,et al. Endometrial effects of intrauterine levonorgestrel. , 2007, Contraception.
[19] H. Croxatto,et al. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. , 2007, Contraception.
[20] M. García-Closas,et al. Reproductive risk factors for endometrial cancer among Polish women , 2007, British Journal of Cancer.
[21] X. Shu,et al. Dietary Folate Intake, MTHFR Genetic Polymorphisms, and the Risk of Endometrial Cancer among Chinese Women , 2007, Cancer Epidemiology Biomarkers & Prevention.
[22] X. Shu,et al. Oral contraceptive and IUD use and endometrial cancer: A population‐based case–control study in Shanghai, China , 2006, International journal of cancer.
[23] H. Checkoway,et al. Menstrual and reproductive factors in relation to risk of endometrial cancer in Chinese women , 2006, Cancer Causes & Control.
[24] A. Ørbo,et al. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. , 2006, Gynecologic oncology.
[25] R. Ness,et al. Inflammation and Endometrial Cancer: A Hypothesis , 2005, Cancer Epidemiology Biomarkers & Prevention.
[26] D. Cheng,et al. Intrauterine devices and reproductive health: American women in feast and famine. , 2004, Contraception.
[27] K. Mishra,et al. Evaluation of endometrial steroid receptors and cell mitotic activity in women using copper intrauterine device: Can Cu‐T prevent endometrial cancer? , 2004, The journal of obstetrics and gynaecology research.
[28] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[29] R. Mikolajczyk,et al. Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. , 2002, American journal of obstetrics and gynecology.
[30] O. Paltiel,et al. IUD use and the risk of endometrial cancer. , 2002, European journal of obstetrics, gynecology, and reproductive biology.
[31] Hoda Anton-Culver,et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States) , 2002, Cancer Causes & Control.
[32] S. Thompson,et al. How should meta‐regression analyses be undertaken and interpreted? , 2002, Statistics in medicine.
[33] M. Thun,et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort , 2002, Cancer.
[34] H. Adami,et al. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[35] J. Freudenheim,et al. Diet in the epidemiology of endometrial cancer in Western New York (United States) , 2000, Cancer Causes & Control.
[36] J. Stanford,et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. , 2000, American journal of obstetrics and gynecology.
[37] J. Paavonen,et al. Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrel. , 2000, Molecular human reproduction.
[38] E. Lazcano-Ponce,et al. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. , 1999, Cancer research.
[39] L. Xiaoqun,et al. The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use , 1999 .
[40] E. Rutanen,et al. The effect of intrauterine levonorgestrel use on the expression of c-JUN, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium. , 1998, Molecular human reproduction.
[41] D. Mishell. Intrauterine devices: mechanisms of action, safety, and efficacy. , 1998, Contraception.
[42] H. Critchley,et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. , 1998, Human reproduction.
[43] L. Brinton,et al. Intrauterine device use and endometrial cancer risk. , 1997, International journal of epidemiology.
[44] M. Thiéry. Pioneers of the intrauterine device. , 1997, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.
[45] N. Weiss,et al. Endometrial cancer in relation to intra‐uterine device use , 1997, International journal of cancer.
[46] K. Rosenblatt,et al. Intrauterine devices and endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. , 1996, Contraception.
[47] C. la Vecchia,et al. Intake of selected micronutrients and the risk of endometrial carcinoma , 1996, Cancer.
[48] I. Milsom,et al. The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status. , 1995, Contraception.
[49] B. Xiao,et al. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. , 1995, Contraception.
[50] E. Rutanen,et al. Effect of intrauterine contraceptive devices on cytokine messenger ribonucleic acid expression in the human endometrium. , 1995, Fertility and sterility.
[51] J. Palmer,et al. The Black Women's Health Study: a follow-up study for causes and preventions of illness. , 1995, Journal of the American Medical Women's Association.
[52] P. Strax,et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. , 1995, Journal of the National Cancer Institute.
[53] C. la Vecchia,et al. Intrauterine device use and risk of endometrial cancer. , 1994, British Journal of Cancer.
[54] W. Thompson,et al. Intra‐uterine contraception and the risk of endometrial cancer , 1993, International journal of cancer.
[55] R. Hoover,et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. , 1992, American journal of obstetrics and gynecology.
[56] J. Fraumeni,et al. A population‐based case‐control study of endometrial cancer in shanghai, china , 1991, International journal of cancer.
[57] Thomas Db,et al. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. , 1991, International journal of cancer.
[58] M. Pike,et al. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. , 1988, British Journal of Cancer.
[59] A. Andrade,et al. Quantitative studies on menstrual blood loss in IUD users. , 1987, Contraception.
[60] E. Shalev,et al. Serum ovarian steroids, prolactin and prostaglandin metabolites in women using the inert intrauterine device , 1987, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[61] P. González-Gancedo,et al. The effect of copper ionsin vivo on specific hormonal endometrial receptors , 1986, Advances in contraception : the official journal of the Society for the Advancement of Contraception.
[62] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[63] D. Ribatti,et al. Possible role of mast cells in the mechanism of action of intrauterine contraceptive devices. , 1984, American journal of obstetrics and gynecology.
[64] T. Luukkainen,et al. Body iron stores and patterns of bleeding after insertion of a levonorgestrel- or a copper-releasing intrauterine contraceptive device. , 1982, Contraception.
[65] M. Pike,et al. Endogenous hormones as a major factor in human cancer. , 1982, Cancer research.
[66] C. la Vecchia,et al. Oestrogens and obesity as risk factors for endometrial cancer in Italy. , 1982, International journal of epidemiology.
[67] P. Ylöstalo,et al. Endometrial estrogen and progestin receptors in women bearing a progesterone-releasing intrauterine device. , 1980, Contraception.
[68] R. Snowden. Analysis of Intrauterine Contraception. Proceedings of the Third International Conference on Intrauterine Contraception . Edited by Hefnawi F. and S. J. Segal. Pp. 490 + xii. (North-Holland, Amsterdam, 1975.)Price US $32.50. , 1976, Journal of Biosocial Science.
[69] S. Segal,et al. Analysis of intrauterine contraception : proceedings of the Third International Conference on Intrauterine Contraception, Cairo, Arab Republic of Egypt, 12-14 December 1974 , 1976 .
[70] J. Bonnar,et al. MENSTRUAL BLOOD-LOSS WITH INTRAUTERINE DEVICES , 1976, The Lancet.
[71] D. Mishell,et al. Progesterone and Estradiol Patterns in Women Using an Intrauterine Contraceptive Device , 1975, Obstetrics and gynecology.
[72] Brenner Pf,et al. Progesterone and estradiol patterns in women using an intrauterine contraceptive device. , 1975 .
[73] D. Mishell,et al. Reactions of human endometrium to the intrauterine foreign body. II. Long term effects on the endometrial histology and cytology. , 1971, American journal of obstetrics and gynecology.
[74] P. Kraft,et al. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976–2004 , 2010, International journal of cancer.
[75] P. Crosignani. Intrauterine devices and intrauterine systems. , 2008, Human reproduction update.
[76] J. Trussell. Contraceptive failure in the United States. , 2004, Contraception.
[77] J. Cheng,et al. The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use. , 1999, Human reproduction.
[78] V. Odlind,et al. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. , 1994, Contraception.
[79] C. la Vecchia,et al. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. , 1993, European journal of cancer.
[80] Society for the Advancement of Contraception , 1989 .
[81] R. Punnonen,et al. Androgen, estrogen and progestin cytosol receptor concentrations in the normal human endometrium. Effects of intrauterine device. , 1984, Gynecologic and obstetric investigation.
[82] T. Luukkainen,et al. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. , 1984, Fertility and sterility.